Swiss lawmakers face crises over pensions, threats, and health risks from China imports

Swiss lawmakers are grappling with multiple pressing issues this year. From funding disputes over pensions to rising threats against politicians, debates have intensified. Meanwhile, health concerns have emerged over imports from Chinese retailers like Temu, Shein, and Wish, and pharmaceutical payments to doctors have hit a record high.

A surge in skin rashes among workers at the Frauenfeld TG distribution centre has raised alarms. Employees handling between 300,000 and 400,000 daily parcels—many from Chinese retailers—report irritations on their hands and forearms. The exact cause remains unclear, but suspicions focus on potential hazards linked to low-cost imports from China.

In politics, intimidation is worsening, particularly for women and minority representatives. A staggering 98% of parliament members have faced threats, defamation, or violence, undermining their work and free expression.

Pension reforms are another flashpoint. Twelve cantons, including Zurich, Bern, and Geneva, now back an initiative for fairer widows' and orphans' pensions. However, the FDP, SVP, and economiesuisse strongly oppose it. The Council of States proposed a mixed funding model—higher payroll contributions and VAT increases—but the National Council rejected this. VAT hikes would disproportionately impact low-income earners, adding to the controversy. Meanwhile, the Council of States delayed until 2025 a decision on funding the 13th AHV pension payment.

Separately, pharmaceutical companies paid Swiss doctors and hospitals a record CHF 262 million in 2024. These funds covered conference fees, consulting, and sponsorships, as firms target prescribers to boost sales—direct marketing to consumers being banned in Switzerland and Europe.

The debates over pension funding, political intimidation, and health risks from imports from China remain unresolved. Parliament's delayed decisions and divided stances suggest further discussions ahead. The record payments to doctors also highlight ongoing scrutiny of pharmaceutical industry influence.